Key result
Late gadolinium enhancement confined to the right ventricular insertion point did not significantly increase the risk of adverse cardiac events compared to no LGE (HR 3.168, p=0.101).
Why the study?
The clinical implication and prognostic significance of late gadolinium enhancement at the right ventricular insertion point in patients with non-ischemic dilated cardiomyopathy had not been elucidated.
Does the presence of late gadolinium enhancement at the right ventricular insertion point affect the risk of adverse cardiac events in patients with non-ischemic dilated cardiomyopathy?
Cohort (n=360)
Yes
Does the presence of late gadolinium enhancement at the right ventricular insertion point affect the risk of adverse cardiac events in patients with non-ischemic dilated cardiomyopathy?
Hazard Ratio: 3.168 (95% CI 0.8–12.541)
Absolute Event Rate: 32% vs 21.6%
p-value: p=0.101
LGE confined to the right ventricular insertion point in NICM patients does not significantly increase the risk of adverse cardiac events and has a better prognosis than a similar extent of LGE in the left ventricle.
No takes yet. Share an insight, caveat, or question.
RVIP-LGE warrants no change in NICM risk stratification; leaves open whether LGE distribution modifies prognosis beyond extent.
Yi et al. (2018) conducted a cohort in Non-ischemic dilated cardiomyopathy (n=360). Late gadolinium enhancement at the right ventricular insertion point (RVIP-LGE) vs. No LGE was evaluated on Composite of all-cause death, hospitalization due to worsening of heart failure, and major arrhythmic events (HR 3.168, 95% CI 0.800-12.541, p=0.101). Late gadolinium enhancement confined to the right ventricular insertion point did not significantly increase the risk of adverse cardiac events compared to no LGE (HR 3.168, p=0.101).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: